The present study, was designed to investigate the role of L-Lysine supplementation to prevent the diabetic complications in type 2 diabetic patients. Therefore, 50 type 2 diabetic patients in both sexes, with no diabetic complications, that received glibenclamide (10 mg/day) and metformin (1000 mg/day) was selected and then divided into two equal groups, control and case (#25 in each). The case group was received L-Lysine sachets (3 g/day) in addition to the above mentioned drugs for three months. The fasting blood samples of all patients were prepared at first and after three months of treatment. After that, some parameters including fasting blood sugar, insulin, glycated hemoglobin, and other glycated proteins were determined in the whole blood or serum of both groups.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT2014120220184N1
Registration date:2017-06-05, 1396/03/15
Registration timing:retrospective
Last update:
Update count:0
Registration date
2017-06-05, 1396/03/15
Registrant information
Name
Seyedeh Zahra Bathaie
Name of organization / entity
Tarbiat Modares University
Country
Iran (Islamic Republic of)
Phone
+98 21 8288 4567
Email address
bathai_z@modares.ac.ir
Recruitment status
Recruitment complete
Funding source
Iran National Science Fundation (INSF)
Expected recruitment start date
2011-12-31, 1390/10/10
Expected recruitment end date
2012-12-31, 1391/10/11
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Investigation of the Effectiveness of L-Lysine Supplementation in the Control of Fasting Blood Sugar in Type 2 Diabetic Patients.
Public title
L-Lysine therapy of type 2 diabetic patients
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion Criteria: Glycated hemoglobin (HbA1c) ≥ 7%; normal serum insulin level; no history of ketoacidosis, cancer, hyper- or hypothyroidism, diabetic ulcer, chronic renal failure, liver cirrhosis, feverish diseases and consumption of corticosteroids; with serum creatinine ≥ 2 mg/dl; no symptom of hypoinsulinemia such as ketonuria, weight loss; serum glucose level more than 400 mg/dl.
Exclusion Criteria: no response to oral agents; need for insulin therapy; appearance of diabetic ulcer or feverish diseases during treatment.